Volume | 218,052 |
|
|||||
News | - | ||||||
Day High | 0.8501 | Low High |
|||||
Day Low | 0.7815 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
ABVC BioPharma Inc | ABVC | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.85 | 0.7815 | 0.8501 | 0.7941 | 0.858 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
1,275 | 218,052 | US$ 0.8153337 | US$ 177,785 | - | 0.6739 - 7.00 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:57:18 | 45 | US$ 0.785 | USD |
ABVC BioPharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
8.34M | 10.56M | - | 152k | -10.52M | -1.00 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
ABVC BioPharma News
Date | Time | Source | News Article |
---|---|---|---|
5/24/2024 | 07:00 | Edgar (US Regulatory) | Form 8-K - Current report |
5/23/2024 | 16:00 | Edgar (US Regulatory) | Form 8-K - Current report |
5/23/2024 | 15:30 | Edgar (US Regulatory) | Form 424B4 - Prospectus [Rule 424(b)(4)] |
5/22/2024 | 16:00 | Edgar (US Regulatory) | Form 424B4 - Prospectus [Rule 424(b)(4)] |
5/22/2024 | 13:31 | Edgar (US Regulatory) | Form 424B4 - Prospectus [Rule 424(b)(4)] |
5/17/2024 | 16:00 | Edgar (US Regulatory) | Form 8-K/A - Current report: [Amend] |
5/17/2024 | 15:01 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
5/15/2024 | 16:00 | Edgar (US Regulatory) | Form NT 10-Q - Notification of inability to timely file Form.. |
5/15/2024 | 08:00 | Edgar (US Regulatory) | Form 8-K - Current report |
5/09/2024 | 08:27 | Edgar (US Regulatory) | Form 8-K - Current report |
4/18/2024 | 08:25 | GlobeNewswire Inc. | AiBtl BioPharma Inc. Acquired TT Life Company, Valued at.. |
4/17/2024 | 08:00 | GlobeNewswire Inc. | ABVC BioPharma Executes a Global Licensing Definitive.. |
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ABVC Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.00 | 1.02 | 0.7815 | 0.9134572 | 220,611 | -0.215 | -21.50% |
1 Month | 1.15 | 1.24 | 0.7815 | 1.06 | 319,906 | -0.365 | -31.74% |
3 Months | 1.20 | 1.73 | 0.7815 | 1.29 | 1,236,033 | -0.415 | -34.58% |
6 Months | 1.51 | 2.45 | 0.7815 | 1.61 | 1,484,383 | -0.725 | -48.01% |
1 Year | 6.898 | 7.00 | 0.6739 | 1.92 | 1,578,097 | -6.11 | -88.62% |
3 Years | 33.20 | 116.883 | 0.6739 | 17.57 | 1,003,895 | -32.42 | -97.64% |
5 Years | 33.20 | 116.883 | 0.6739 | 17.57 | 1,003,895 | -32.42 | -97.64% |
ABVC BioPharma Description
ABVC BioPharma licenses promising medical research conducted in the Asia-Pacific region and enlists top-ranked principal investigators in the United States to conduct Phase II clinical trials. We specialize in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes that represent enormous commercial potential. |